Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Incidence of Bone Metastases Was Reduced<br />
in Patients Receiving ZOL<br />
BMF survival, %<br />
100<br />
99<br />
98<br />
97<br />
96<br />
95<br />
94<br />
93<br />
92<br />
Hazard ratio (95% CI)<br />
Events, n vs No ZOL P value<br />
ZOL 16 0.676 (0.359, 1.272) .224<br />
No ZOL 24<br />
0 12 24 36 48 60 72 84<br />
Time since randomization, months<br />
Median follow-up = 48 months.<br />
BMF = Bone metastases-free; CI = Confidence interval; ZOL = Zoledronic acid.<br />
13
Change language